Clene Reports Full Year 2025 Financial Results and Recent Operating Highlights

Core Insights - Clene Inc. reported its full year 2025 financial results and updates on its CNM-Au8 programs, focusing on treatments for neurodegenerative diseases like ALS and MS [1][2]. Financial Performance - Clene's total revenue for 2025 was $200 million, a decrease from $342 million in 2024, primarily due to lower product and royalty revenues [18]. - Research and development expenses decreased to $14 million in 2025 from $20.1 million in 2024, attributed to the completion of certain trials and reduced regulatory activity [10]. - General and administrative expenses also fell to $9.2 million in 2025 from $13.3 million in 2024, mainly due to lower insurance and legal fees [11]. - The net loss for 2025 was $26.2 million, or $2.65 per share, compared to a net loss of $39.4 million, or $5.67 per share, in 2024 [13]. Clinical Developments - Clene is preparing for a Type C meeting with the FDA to discuss biomarker and survival data for CNM-Au8, which could lead to an NDA filing for ALS by the end of June 2026 [2][3]. - The company reported significant reductions in neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) biomarkers, correlating with improved survival in ALS patients [4]. - CNM-Au8 has shown a favorable safety profile with no significant safety concerns reported across over 1,100 patient years of exposure [5]. Corporate Updates - Clene completed an oversubscribed registered direct offering of over $28 million in January 2026, with an initial tranche of over $6 million expected to fund operations through the third quarter of 2026 [6][8]. - As of December 31, 2025, Clene's cash and cash equivalents totaled $5.2 million, down from $12.2 million in 2024, but expected to be supplemented by the recent financing [9]. Future Outlook - Clene aims to initiate a confirmatory Phase 3 trial in ALS and continue working with the FDA on a Phase 3 trial in MS, with the expectation that patients with various neurodegenerative conditions may benefit from CNM-Au8 treatment [2][3].